Stock Pulse
Cigna Group (CI) faces an antitrust investigation in Canada for its Express Scripts unit's alleged anti-competitive practices, including patient steering and reduction of pharmacy margins [1]. This investigation poses risks to Cigna's Canadian operations, reputation, and potential fines [1]. Despite this, Cigna demonstrated strong long-term revenue growth and economies of scale [5], and its stock recently received an improved Relative Strength Rating [8]. However, slower customer growth presents a challenge [5], and the FTC lawsuit against Express Scripts for alleged anti-competitive practices continues, posing significant legal and financial risks [6]. Cigna will release its Q1 2025 financial results on May 2nd [7]. While the company engaged in positive PR through community support initiatives [2], the overall sentiment is weighed down by the ongoing legal challenges. [1], [6]